MAPT and Alzheimer disease: Furthermore, our findings suggest that VX-765 not only blocks sevoflurane-induced pyroptosis but also suppresses Aβ deposition and tau phosphorylation in microglia, suggesting that VX-765 could represent a novel therapeutic intervention for AD.